Windtree Therapeutics, a Nasdaq-listed biotech firm, has announced plans to purchase up to $700 million in BNB, following the cryptocurrency's all-time high price. The company is raising $520 million to facilitate the purchase, having previously planned to buy $200 million worth of BNB. It aims to partner with the Kraken exchange for asset custody. Windtree's CEO emphasized the importance of securing additional funds for its strategy. This move is part of a larger trend where publicly traded companies are investing in various cryptocurrencies, not just Bitcoin, to bolster their stock value. Despite a 5% decline in stock price recently, Windtree's shares have surged by 162% over the past month. Other companies, like Nano Labs, also announced significant BNB purchases recently, illustrating the growing interest from corporations in holding digital assets.

Source šŸ”—